ONCOLife Issues
Featured Articles
Trending Articles
Designing Digital Healthcare Systems for the Future of Patient-Centered Care
Digital Health | 4 March 2026
Gut Bacteria Decide Whether Nutrients Feed Tumors or Fuel Immunity
ONCOLife | 13 February 2026
Amivantamab Plus Chemotherapy Shows Promising Responses in Colorectal Cancer
Clinical Trials | 11 January 2026
Novartis Expands US Radioligand Manufacturing With $23 Billion Investment in Florida
Pharma | 9 January 2026
Rewiring RNA: Antisense RNA Therapy Exposes a New Weakness in Pancreatic Cancer
ONCOLife | 8 January 2026
FDA Approves First Subcutaneous Amivantamab Plus Lazertinib for EGFR+ Lung Cancer
FDA & EMA | 18 December 2025
Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer
Clinical Trials | 18 December 2025
Artificial Intelligence Detects Pancreatic Cancer More Accurately Than Radiologists
AI | 12 December 2025
FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer
FDA & EMA | 16 December 2025
Less Toxic, More Effective: RW Evidence Supports Reduced Immunotherapy Dose in Melanoma
Clinical Trials | 14 December 2025
Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma
Clinical Trials | 10 December 2025
FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy
FDA & EMA | 12 December 2025
Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer
Clinical Trials
10 December 2025
Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer
Clinical Trials
10 December 2025
Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas
ONCOLife
8 December 2025
Nanotherapy Reprograms Glioblastoma Immunity Through Nose-to-Brain Delivery
ONCOLife
2 December 2025
Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer
Clinical Trials
6 December 2025
Blood-Based cfDNA Test Demonstrates Potential for Detecting Lung Cancer in Nonsmokers
ONCOLife
5 December 2025
FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers
FDA & EMA
26 November 2025
Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer
FDA & EMA
20 November 2025
FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma
FDA & EMA
19 November 2025
FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia
FDA & EMA
14 November 2025
Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer
ONCOLife
5 November 2025